Abstract
4028 Background: With its inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib (S) is an oral anticancer agent targeting Ras-dependent signal transdu...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
